Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-01-06Clinical Trial Update: Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer [Phase 2]
Phase 2 trial of ipilimumab plus nivolumab in molecularly selected castration-resistant prostate cancer has completed.
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer [Phase 2]
Phase 2 trial evaluating re-treatment with Lutetium-177–PSMA in men with metastatic castration-resistant prostate cancer; the study is curre…
-
CLINICAL_TRIALS research · 2026-01-05Clinical Trial Update: Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma [Phase 1]
Phase I clinical trial evaluating the combination of Docetaxel and Lutetium-177 PSMA-I&T as first-line treatment for metastatic castration-r…
-
CLINICAL_TRIALS research · 2025-12-31Clinical Trial Update: A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study [Phase 1]
Phase 1 RADIODOSE study assessing radiation dosimetry, safety, and tolerability of extended Lutetium-177 Vipivotide Tetraxetan in chemo-naïv…
-
CLINICAL_TRIALS research · 2025-12-31Clinical Trial Update: Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer [NA]
This clinical trial update describes evaluating intrinsic validity of molecular marker detection in tumoral DNA to predict the efficacy of L…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-12-31Clinical Trial Update: Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc [Phase 2]
A randomized Phase II trial is evaluating targeted radiation without castration for metastatic castration-resistant prostate cancer, and the…
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer [Phase 2]
This Phase 2 trial compares dapagliflozin plus a next-generation hormonal agent versus a single hormonal agent in metastatic castration-resi…
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: 68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]
Clinical trial update for two PSMA-targeted radiopharmaceuticals (68Ga-PSMA-0057 and 177Lu-PSMA-0057) being studied for PSMA-positive metast…
-
CLINICAL_TRIALS trial_result · 2025-12-30Clinical Trial Update: Post Marketing Study on Pluvicto in Korea
A post-marketing study of Pluvicto (Lutetium-177-PSMA-617) in Korea for metastatic castration-resistant prostate cancer is currently recruit…
-
CLINICAL_TRIALS research · 2025-12-26Clinical Trial Update: Prospective Evaluation of Imaging Response Biomarkers During [177Lu]Lu-PSMA in Metastatic Castration-resistant Prostate Cancer
This clinical trial update describes a prospective study evaluating imaging response biomarkers during [177Lu]Lu-PSMA therapy in metastatic …
-
CLINICAL_TRIALS research · 2025-12-26Clinical Trial Update: Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)
Real-world clinical study evaluating outcomes for metastatic castration-resistant prostate cancer patients treated with the olaparib and abi…
-
CLINICAL_TRIALS research · 2025-12-24Clinical Trial Update: Four-Timepoint Multi-tracer PET Imaging to Characterize Metastatic prOstate Cancer Heterogeneity [NA]
This clinical trial update describes a study using four-timepoint multi-tracer PET imaging to characterize heterogeneity in metastatic castr…
-
CLINICAL_TRIALS research · 2025-12-23Clinical Trial Update: Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer [Phase 2]
This Phase 2 trial evaluates cabazitaxel, carboplatin, and cetrelimab with or without niraparib for aggressive variant metastatic prostate c…
-
CLINICAL_TRIALS research · 2025-12-23Clinical Trial Update: Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer. [Phase 2]
Phase 2 clinical trial assessing detection of metastases using PyL PET/CT in patients starting enzalutamide for untreated castration-resista…
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer [Phase 1]
An ongoing Phase 1 trial evaluating Ac-225-PSMA-62 for oligometastatic hormone-sensitive and metastatic castration-resistant prostate cancer…
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: TmPSMA-02 in mCRPC [Phase 1]
This update indicates a Phase 1 clinical trial of TmPSMA-02 for metastatic castration-resistant prostate cancer is currently recruiting at t…
-
CLINICAL_TRIALS trial_result · 2025-12-22Clinical Trial Update: Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer [Phase 1]
Phase 1 safety and tolerability study of CC-94676 in metastatic castration-resistant prostate cancer has completed.
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating oral HP518 in metastatic castration-resistant prostate cancer to assess safety, pharmacokinetics, and …
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer [Phase 2]
This update describes a Phase 2 clinical trial evaluating SX-682 in combination with enzalutamide for ARPI-resistant metastatic castration-r…
-
CLINICAL_TRIALS trial_result · 2025-12-19Clinical Trial Update: Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations [Phase 4]
A Phase 4 clinical trial evaluating olaparib for efficacy and safety in Chinese patients with metastatic castration-resistant prostate cance…
-
CLINICAL_TRIALS research · 2025-12-19Clinical Trial Update: Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer [Phase 2]
A phase 2 study of galunisertib in combination with enzalutamide for metastatic castration-resistant prostate cancer; the trial is currently…
-
CLINICAL_TRIALS trial_result · 2025-12-18Clinical Trial Update: Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) [Phase 2]
Completed Phase 2 study evaluating cabozantinib in metastatic castration-resistant prostate cancer (mCRPC).
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of INV-9956 in adults with m…
-
CLINICAL_TRIALS trial_result · 2025-12-15Clinical Trial Update: A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer [Phase 1, Phase 2]
A completed Phase 1/2 clinical trial assessed the combination of talazoparib and temozolomide in prostate cancer, including castration-resis…
-
CLINICAL_TRIALS research · 2025-12-09Clinical Trial Update: XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 2]
Phase 2 clinical trial evaluating XL092 in metastatic castration-resistant prostate cancer is currently recruiting.